©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2025; 13(14): 98769
Published online May 16, 2025. doi: 10.12998/wjcc.v13.i14.98769
Published online May 16, 2025. doi: 10.12998/wjcc.v13.i14.98769
Insight into the efficacy and safety of pirfenidone: The treatment of idiopathic pulmonary fibrosis
Li-Ying Xu, Department of Medical Administration, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, Zhejiang Province, China
Yi Yu, The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310051, Zhejiang Province, China
Lu-Sha Cen, Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, Zhejiang Province, China
Co-first authors: Li-Ying Xu and Yi Yu.
Author contributions: Xu LY wrote the manuscript; Yu Y prepared materials and unified the style; Cen LS provided the resources and funds; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest regarding the publication of this article.
Corresponding author: Lu-Sha Cen, PhD, Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), No. 54 Youdian Road, Hangzhou 310006, Zhejiang Province, China.
Received: July 5, 2024
Revised: December 9, 2024
Accepted: January 2, 2025
Published online: May 16, 2025
Processing time: 194 Days and 4.7 Hours
Revised: December 9, 2024
Accepted: January 2, 2025
Published online: May 16, 2025
Processing time: 194 Days and 4.7 Hours
Core Tip
Core Tip: Early intervention is essential for idiopathic pulmonary fibrosis (IPF). Lei et al have shown that timely initiation of pirfenidone treatment in individuals diagnosed with IPF can effectively reduce the occurrence of adverse reactions. Moreover, choosing an appropriate pharmaceutical approach or timing for IPF treatment could be beneficial; however, further evidence is required.